| European Case Law Identifier: | ECLI:EP:BA:2004:T060902.20041027 | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Date of decision: | 27 October 2004 | ||||||||
| Case number: | T 0609/02 | ||||||||
| Application number: | 91917435.9 | ||||||||
| IPC class: | G01N 33/74 | ||||||||
| Language of proceedings: | EN | ||||||||
| Distribution: | B | ||||||||
| Download and more information: |
|
||||||||
| Title of application: | Methods mediated by the proto-oncogenic protein complex AP-1 | ||||||||
| Applicant name: | THE SALK INSTITUTE FOR BIOLOGICAL STUDIES | ||||||||
| Opponent name: | Karo Bio AB Astra AB |
||||||||
| Board: | 3.3.08 | ||||||||
| Headnote: | - | ||||||||
| Relevant legal provisions: |
|
||||||||
| Keywords: | Sufficiency of disclosure - no | ||||||||
| Catchwords: |
If the description of a patent specification provides no more than a vague indication of a possible medical use for a chemical compound yet to be identified, later more detailed evidence cannot be used to remedy the fundamental insufficiency of disclosure of such subject-matter. |
||||||||
| Cited decisions: |
|
||||||||
| Citing decisions: | |||||||||
Source: http://www.epo.org/law-practice/case-law-appeals/recent/t020609eu1.html
Date retrieved: 17 May 2021